Strumento inattivo

Altre lingue Audentes Therapeutics, Inc.

Azioni

US05070R1041

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	14/03
Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	08/11/22
Taysha Gene Therapies, Inc. announced that it expects to receive $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	21/10/22
Audentes Therapeutics, Inc. Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy	25/12/20
Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy	21/08/20
Audentes Therapeutics, Inc. Appoints Julie Person as Senior Vice President, Human Resources	21/04/20
Audentes Therapeutics, Inc. Plans to Build New Gene Therapy Manufacturing Facility in Sanford, North Carolina	18/02/20
AUDENTES THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	15/01/20
Audentes Therapeutics, Inc. Announces Management Changes	15/01/20
Audentes Therapeutics, Inc. Approves a Change in the Company’s Fiscal Year to End on March 31	15/01/20
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P TMI Index	15/01/20
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Biotechnology Select Industry Index	15/01/20
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Global BMI Index	15/01/20
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Composite Index	14/01/20
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Biotechnology Index	14/01/20
Astellas US Holding, Inc. completed the acquisition of Audentes Therapeutics, Inc..	14/01/20
Takeda Pharmaceutical : Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million	27/12/19
Roche : dives deeper into gene therapy with $1.15 billion Sarepta licensing deal	23/12/19
AUDENTES THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	16/12/19
Japanese shares slip on concerns of longer trade war	04/12/19

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Audentes Therapeutics, Inc.

Azioni

US05070R1041

Altre lingue

Filtri